Pancreatic Insufficiency Clinical Trial
Official title:
Pilot and Feasibility Study for the Treatment of Pre-diabetes in Patients With Cystic Fibrosis
Verified date | January 2013 |
Source | Arbelaez, Ana Maria |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
The purpose of this study is to provide the necessary data and experience to design a larger, full scale clinical trial to determine if a certain medicine (repaglinide), which increases the amount of insulin secreted by the pancreas, can improve the nutritional status and pulmonary function of adolescents and young adults with cystic fibrosis and prediabetes by improving blood glucose control. The investigators are also trying to determine the relationship between systemic inflammatory factors and glucose impairment.
Status | Completed |
Enrollment | 40 |
Est. completion date | January 2013 |
Est. primary completion date | January 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 12 Years to 24 Years |
Eligibility |
Inclusion Criteria: - Male or females 12 -24 years old - Diagnosis of Cystic Fibrosis by sweat test with exocrine pancreatic insufficiency - Must have a glucose pattern by Oral Glucose Tolerance Test with fasting blood glucose <126 mg/dl and 2 hour: 140 - 199 mg/dl or >200 mg/dl. - Weight must be stable within 5% for 3 months prior to initiation visit - Must be able to reproducibly perform spirometry based on American Thoracic Society guidelines Exclusion Criteria: - Patients receiving growth hormone therapy or taking insulin - Patients with evidence of liver dysfunction - Patients who are status-post lung or liver transplantation - Patients who have received systemic steroids for more than 28 days during the 6 months prior to the study - Patients with active ABPA on steroids - Patients taking medications that affect glucose metabolism or contraindicated with repaglinide |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Country | Name | City | State |
---|---|---|---|
United States | Washington University School of Medicine | St. Louis | Missouri |
Lead Sponsor | Collaborator |
---|---|
Arbelaez, Ana Maria | National Institutes of Health (NIH), Novo Nordisk A/S, Washington University School of Medicine |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | feasibility | every 3 months for 2 years | No | |
Secondary | 1.BMI, z-score, DEXA scan,2.FEV1, FVC, 3.HOMA, QUICKI, 4.systemic inflammatory markers. | Every 3-6 months over a 2-year period | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03279653 -
Pancreatic Exocrine Insufficiency After Bariatric Surgery
|
N/A | |
Recruiting |
NCT01851694 -
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
|
N/A | |
Completed |
NCT01710644 -
Efficacy and Tolerability of NM-BL in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
|
Phase 1/Phase 2 | |
Completed |
NCT01988350 -
Pancreatic Insufficiency Secondary to Tobacco Exposure
|
N/A | |
Active, not recruiting |
NCT01012908 -
Clinical Non-Inferiority of Pancreatic Enzymes (Norzyme ® - Bergamo) Compared To Creon ® (Solvay Pharmaceutical) in Patients With Exocrine Pancreatic Insufficiency
|
Phase 2/Phase 3 | |
Completed |
NCT01879228 -
Effect of Chronic Incretin-based Therapy in Cystic Fibrosis
|
N/A | |
Completed |
NCT00705978 -
Creon 40,000 for Treatment of PEI (Pancreatic Exocrine Insufficiency) Due to Chronic Pancreatitis
|
Phase 3 | |
Completed |
NCT00095732 -
Oral TheraCLEC™ - Total in Cystic Fibrosis Subjects With Exocrine Pancreatic Insufficiency
|
Phase 2 | |
Completed |
NCT00513682 -
Efficacy and Safety of Ultrase® MT20 in Improving the Coefficient of Fat Absorption (CFA) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI)
|
Phase 3 | |
Recruiting |
NCT05466838 -
PERT to Improve Quality of Life in Patients Undergoing Pancreaticoduodenectomy: A Pilot Randomized Controlled Trial
|
N/A | |
Completed |
NCT02979340 -
MRI to Characterize and Predict CF Liver Disease in PUSH Cohort
|
||
Completed |
NCT00432861 -
Evaluation of the Safety and Efficacy of Pancrecarb® MS-16 in Cystic Fibrosis
|
Phase 3 | |
Completed |
NCT00406536 -
Study of LYM-X-SORB™ to Improve Fatty Acid and Choline Status in Children With CF and PI
|
Phase 2 | |
Completed |
NCT01144507 -
Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis
|
||
Completed |
NCT05700604 -
Hypoglycemia and Glucagon Response in CF
|
||
Terminated |
NCT02985801 -
PERT for Treatment of Exocrine Pancreatic Insufficiency in Patients With Unresectable Pancreatic Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03551691 -
Proton Pump Inhibitors (PPI) and Fat Absorption in Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (EPI)
|
Phase 2 | |
Recruiting |
NCT03450772 -
Equivalence Study to Compare Two Strengths of Creon in China
|
Phase 3 | |
Completed |
NCT00572975 -
Malabsorption Blood Test:Toward a Novel Approach to Quantify Steatorrhea
|
Phase 4 | |
Completed |
NCT00880100 -
Use of Ultrase® MT12 in Young Cystic Fibrosis Children (CF)
|
Phase 3 |